Voyager Therapeutics, Inc.
NASDAQ:VYGR
7.01 (USD) • At close November 11, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 250.008 | 40.907 | 37.415 | 171.128 | 104.391 | 7.619 | 10.135 | 14.22 | 17.334 | 0 | 0 |
| Cost of Revenue
| 4.441 | 6.191 | 73.787 | 108.753 | 119.735 | 64.905 | 62.26 | 42.249 | 27.679 | 8.898 | 4.632 |
| Gross Profit
| 245.567 | 34.716 | -36.372 | 62.375 | -15.344 | -57.286 | -52.125 | -28.029 | -10.345 | -8.898 | -4.632 |
| Gross Profit Ratio
| 0.982 | 0.849 | -0.972 | 0.364 | -0.147 | -7.519 | -5.143 | -1.971 | -0.597 | 0 | 0 |
| Reseach & Development Expenses
| 87.731 | 60.764 | 73.787 | 108.753 | 119.735 | 64.905 | 62.26 | 42.249 | 27.679 | 8.898 | 4.632 |
| General & Administrative Expenses
| 35.822 | 30.98 | 37.246 | 34.991 | 36.335 | 33.809 | 19.738 | 13.27 | 9.909 | 5.469 | 2.9 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 35.822 | 30.98 | 37.246 | 34.991 | 36.335 | 33.809 | 19.738 | 13.27 | 9.909 | 5.469 | 2.9 |
| Other Expenses
| 0.003 | 4.445 | 2.421 | 7.698 | 8.082 | 2.627 | 1.165 | 1.158 | -9.418 | 0 | 0 |
| Operating Expenses
| 123.553 | 91.744 | 111.033 | 143.744 | 156.07 | 98.714 | 81.998 | 55.519 | 37.588 | 14.367 | 2.9 |
| Operating Income
| 122.014 | -50.837 | -73.618 | 27.384 | -51.679 | -91.095 | -71.863 | -41.299 | -20.254 | -14.367 | -7.532 |
| Operating Income Ratio
| 0.488 | -1.243 | -1.968 | 0.16 | -0.495 | -11.956 | -7.091 | -2.904 | -1.168 | 0 | 0 |
| Total Other Income Expenses Net
| 11.724 | 4.445 | 2.421 | 9.357 | 8.082 | 2.627 | 1.165 | 1.158 | -9.418 | -1.95 | -0.134 |
| Income Before Tax
| 133.738 | -46.392 | -71.197 | 36.741 | -43.597 | -88.468 | -70.698 | -40.141 | -29.672 | -16.317 | -7.666 |
| Income Before Tax Ratio
| 0.535 | -1.134 | -1.903 | 0.215 | -0.418 | -11.611 | -6.976 | -2.823 | -1.712 | 0 | 0 |
| Income Tax Expense
| 1.408 | 0.016 | -5.165 | -1.659 | -2.765 | -0.18 | -1.595 | 0.052 | -0.6 | 0 | -0.134 |
| Net Income
| 132.33 | -46.408 | -66.032 | 36.741 | -40.832 | -88.288 | -70.698 | -40.193 | -29.672 | -16.317 | -7.666 |
| Net Income Ratio
| 0.529 | -1.134 | -1.765 | 0.215 | -0.391 | -11.588 | -6.976 | -2.827 | -1.712 | 0 | 0 |
| EPS
| 3.08 | -1.21 | -1.75 | 0.99 | -1.14 | -2.75 | -2.64 | -1.59 | -7.08 | -1.11 | -16.552 |
| EPS Diluted
| 2.97 | -1.21 | -1.75 | 0.98 | -1.14 | -2.75 | -2.64 | -1.59 | -7.08 | -1.11 | -16.552 |
| EBITDA
| 126.455 | -50.837 | -73.618 | 31.201 | -51.679 | -91.095 | -71.863 | -41.299 | -20.254 | -14.183 | -0.134 |
| EBITDA Ratio
| 0.506 | -1.243 | -1.968 | 0.182 | -0.495 | -11.956 | -7.091 | -2.904 | -1.168 | 0 | 0 |